# A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

> **NCT05318339** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Carcinoma, Transitional Cell
- HER-2 Gene Amplification

## Interventions

- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT05318339
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-10
- **Primary completion:** 2024-03-10
- **Final completion:** 2024-12-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05318339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05318339, "A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05318339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*